The use of ciclosporin in psoriasis

References

• Borel J. F., Feurer C., Gubler H. U. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468–75
   PubMedGoogle Scholar
• Nicolas J. F., Chamchick N., Thivolet J., Wijdenes G., Morel P., Revillard J. P. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321
   PubMed Web of Science ®Google Scholar
• Gottlieb S. L., Gilleaudeau P., Johnson R., Estes L., Woodworth T. G., Gottlieb A. B., et al. Response of psoriasis to a lymphocyte‐selective toxin (DAB389IL‐2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442–7
   PubMed Web of Science ®Google Scholar
• Mease P. J., Goffe B. S., Metz J., Vanderstoep A., Finck B., Burge D. T. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90
   PubMed Web of Science ®Google Scholar
• Oh C. J., Das K. M., Gottlieb A. B. Treatment with anti‐tumor necrosis factor α (TNFα) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829–30
   PubMed Web of Science ®Google Scholar
• Liu J., Farmer J. D., Lane W. S., Friedman J., Weissman I., Schreiber S. L. Calcineurin is a common target of cyclophylin‐cyclosporin A and FKBP‐FK506 complexes. Cell 1991; 66: 807–15
   PubMed Web of Science ®Google Scholar
• Thompson C. B., Lindsten T., Ledbetter J. A., Kunkel S. L., Young H. A., Emerson S. G., et al. CD28 activation pathway regulates the production of multiple T‐cell‐derived lymphokines/cytokines. Proc Natl Acad Sci U S A 1989; 86: 1333–7
   PubMed Web of Science ®Google Scholar
• Elder J. T., Hammerberg C., Cooper K. D., Kojima T., Nair R. P., Ellis C. N., et al. Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine‐stimulated cultured keratinocytes. J Invest Dermatol 1993; 101: 761–6
   Google Scholar
• Cooper K. D., Baadsgaard O., Ellis C. N., Duell E., Voorhees J. J. Mechanisms of cyclosporine A inhibition of antigen presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94: 649–56
   PubMed Web of Science ®Google Scholar
• Demidem A., Taylor J. R., Grammer S. F., Streilein J. W. T‐lymphocyte‐activating properties of epidermal antigen‐presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen‐presenting cells resemble cultured normal Langerhans cells. J Invest Dermatol 1991; 97: 454–60
   PubMedGoogle Scholar
• Stellato C., de Paulis A., Ciccarelli A. Anti‐inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992; 98: 800–4
   PubMed Web of Science ®Google Scholar
• Triggiani M., Cirillo R., Lichtenstein L. M., Marone G. Inhibition of histamine and prostaglandin D2 release from human lung mast cells by cyclosporin A. Int Arch Allergy Appl Immunol 1989; 88: 253–5
   Google Scholar
• Al‐Daraji W. I., Grant K. R., Ryan K., Saxton A., Reynolds N. J. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002; 118: 779–88
   PubMed Web of Science ®Google Scholar
• Kanitakis J., Thivolet J. Cyclosporin. An immunosuppressant affecting epithelial cell proliferation. Arch Dermatol 1990; 126: 369–75
   PubMed Web of Science ®Google Scholar
• Karashima T., Hachisuka H., Sasai Y. FK506 and cyclosporin A inhibit growth factor‐stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci 1996; 12: 246–54
   PubMedGoogle Scholar
• Fisher G. J., Duell E. A., Nickoloff B. J., Annesley T. M., Kowalke J. K., Ellis C. N., et al. Levels of cyclosporine in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum‐free versus serum‐containing media. J Invest Dermatol 1988; 91: 142–6
   PubMed Web of Science ®Google Scholar
• Urabe A., Kanitakis J., Viac J., Thivolet J. Cyclosporin A inhibits directly in vivo keratinocyte proliferation of living human skin. J Invest Dermatol 1989; 92: 755–7
   Web of Science ®Google Scholar
• Won Y. H., Sauder D. N., McKenzie R. C. Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol 1994; 130: 312–19
   PubMed Web of Science ®Google Scholar
• Niederberger W., Lemaire M., Maurer G., et al. Distribution and binding of cyclosporine in blood and tissue. Transplant Proc 1983; 15: 2419–21
   Web of Science ®Google Scholar
• Lemaire M., Tillement J. P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982; 34: 715–18
   PubMed Web of Science ®Google Scholar
• Ptachcinski R. J., Venkataramanan R., Burckart G. J. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107–32
   PubMed Web of Science ®Google Scholar
• Erkko P., Granlund H., Nuutinen M., Reitamo S. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br J Dermatol 1997; 136: 82–8
   PubMed Web of Science ®Google Scholar
• Wood A. J., Maurer G., Niederberger W., Beveridge T., et al. Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 1983; 15: 2409–12
   Web of Science ®Google Scholar
• Elder C. A., Moore M., Chang C. T., Jin J., Charnick S., Nedelman J., et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865–75
   PubMed Web of Science ®Google Scholar
• Mueller E. A., Kovarik J. M., van Bree J. B., Grevel J., Lucker P. W., Kutz K. Influence of a fat‐rich meal on the pharmacokinetics of a new oral formulation of cyclosporin in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151–5
   PubMed Web of Science ®Google Scholar
• Chawla M., Ali M., Marks R. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis. Br J Dermatol 1996; 135((Suppl 48))S9–S14
   Google Scholar
• Koo J. A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol 1998; 139: 88–95
   PubMed Web of Science ®Google Scholar
• Mueller W., Herrman H. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555
   PubMed Web of Science ®Google Scholar
• Ellis C. N., Gorsulowsky D. C., Hamilton T. A., Billings J. K., Brown M. D., Headington J. T., et al. Cyclosporin improves psoriasis in a double‐blind study. JAMA 1986; 256: 3110–16
   PubMed Web of Science ®Google Scholar
• Van Hooff J. P., Leunissen K. M. L., Van der Staak W. Cyclosporin and psoriasis. Lancet 1985; 1: 335
   PubMed Web of Science ®Google Scholar
• Picascia D. D., Garden J. M., Freinkel R. K., Roenigk H. H Jr. Treatment of resistant severe psoriasis with systemic cyclosporin. J Am Acad Dermatol 1987; 17: 408–14
   PubMed Web of Science ®Google Scholar
• Van Joost T., Bos J. D., Heule F., Meinardi M. M. Low‐dose cyclosporin A in severe psoriasis. A double‐blind study. Br J Dermatol 1988; 118: 183–90
   PubMed Web of Science ®Google Scholar
• Ellis C. N., Fradin M. S., Messana J. M., Brown M. D., Siegel M. T., Hartley A. H., et al. Cyclosporine for plaque‐type psoriasis. Results of a multidose, double‐blind trial. N Engl J Med 1991; 324: 277–84
   PubMed Web of Science ®Google Scholar
• Amerio P., Gravante M., Andreassi M., Masci S. Cyclical immunotherapy in patients with psoriasis. Acta Derm Venereol 1994; Suppl 186: 101–2
   Google Scholar
• Griffiths C. E. M., Powles A. V., McFadden J., Baker B. S., Valdimarsson H., Fry L. Long‐term cyclosporin for psoriasis. Br J Dermatol 1989; 120: 253–60
   PubMedGoogle Scholar
• Levell N. J., Shuster S., Munro C. S., Friedmann P. S. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75: 65–9
   PubMed Web of Science ®Google Scholar
• Harper J. I., Keat A. C., Staughton R. C. Cyclosporin for psoriasis. Lancet 1984; 2: 981–2
   PubMed Web of Science ®Google Scholar
• Van Hooff J. P., Leunissen K. M. L., v d Staak W. Cyclosporin and psoriasis. Lancet 1985; 1: 335
   PubMed Web of Science ®Google Scholar
• Fry L., Griffiths C. E. M., Powles A. V., Baker B. S., Valdimarsson H. Long‐term cyclosporine in the management of psoriasis. Transplant Proc 1988; 20((Suppl 4))23–5
   Google Scholar
• Higgins E., Munro C., Marks J., Friedmann P. S., Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 1989; 121: 71–4
   PubMed Web of Science ®Google Scholar
• Dubertret L., Perussel M., Robiola O., Feutren G. Cyclosporin in psoriasis. A long‐term randomised study on 37 patients. Acta Derm Venereol 1989; Suppl 146: 36
   Google Scholar
• Heule F., Bousema M. T., Laeijendecker R., van Joost T. Three long‐term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol Suppl 1989; 146: 171–5
   Google Scholar
• Cimitan A., Fantini F., Giannetti A. Clinical trial with cyclosporin A. Acta Derm Venereol 1989; Suppl 146: 159–62
   Google Scholar
• Timonen P., Friend D., Abeywickrama K., Laburte C., von Graffenried B., Feutrien G. Efficacy of low‐dose cyclosporin A in psoriasis: results of dose‐finding studies. Br J Dermatol 1990; 122((Suppl 36))33–9
   Google Scholar
• Korstanje M. J., Van de Staak W. J. Long‐term treatment of psoriasis with cyclosporin A – side‐effects, minimal effective dose and cyclosporin blood levels. Clin Exp Dermatol 1991; 16: 8–10
   PubMed Web of Science ®Google Scholar
• Christophers E., Mrowietz U., Henneicke H. H., Farber L., Welzel D. Cyclosporine in psoriasis: a multicenter dose‐finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992; 26: 86–90
   PubMed Web of Science ®Google Scholar
• Anonymous. Short‐ and long‐term considerations concerning the management of plaque psoriasis with low‐dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993; 187((Suppl 1))19–29
   Google Scholar
• Anonymous. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque‐form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology 1993; 187((Suppl 1))8–18
   Google Scholar
• Laburte C., Grossman R., Abi‐Rached J., Abeywickrama K. H., Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long‐term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366–75
   PubMed Web of Science ®Google Scholar
• Finzi A. F., Mozzanica N., Cattaneo A., Chiappino G., Pigatto P. D. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989; 21: 91–7
   PubMed Web of Science ®Google Scholar
• Grossman R. M., Chevret S., Abi‐Rached J., Blanchet D., Dubertret L. Long‐term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623–9
   PubMedGoogle Scholar
• Berth‐Jones J., Henderson C. A., Munro C. S., Rogers S., Chalmers R. J., Boffa M. J., et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study. Br J Dermatol 1997; 136: 527–30
   PubMedGoogle Scholar
• Lowe N. J., Wieder J. M., Rosenbach A., Johnson K., Kunkel R., Bainbridge C., et al. Long‐term low‐dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710–19
   PubMed Web of Science ®Google Scholar
• Touw C. R., Hakkaart‐van Roijen L., Verboom P., Paul C., Rutten F. F., Finlay A. Y. Quality of life outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967–72
   PubMed Web of Science ®Google Scholar
• Salek M. S., Finlay A. Y., Lewis J. J., Sumner M. I. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual Life Res 2004; 13: 91–5
   PubMed Web of Science ®Google Scholar
• Powles A. V., Baker B. S., Valdimarsson H., Hulme B., Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol 1990; 122((Suppl 36))13–19
   PubMedGoogle Scholar
• Levell N. J., Shuster S., Munro C. S., Friedmann P. S. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75: 65–9
   PubMed Web of Science ®Google Scholar
• Mahrle G., Schulze H. J., Farber L., Weidinger G., Steigleder G. K. Low‐dose short‐term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88
   PubMed Web of Science ®Google Scholar
• Heydendael V. M., Spuls P. I., Opmeer B. C., de Borgie C. A., Reitsma J. B., Goldschmidt W. F., et al. Methotrexate versus cyclosporine in moderate‐to‐severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658–65
   PubMed Web of Science ®Google Scholar
• Sandhu K., Kaur I., Kumar B., Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458–63
   PubMed Web of Science ®Google Scholar
• Davison S. C., Morris‐Jones R., Powles A. V., Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405–7
   PubMed Web of Science ®Google Scholar
• Higgins E., Munro C., Marks J., Friedmann P. S., Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 1989; 121: 71–4
   PubMed Web of Science ®Google Scholar
• Sutthipisal N., Sriwatsantsak J., Sirimachan S., Nitidandhabaprabhas P. The use of cyclosporin A in a case of recalcitrant erythrodermic psoriasis. J Int Med Res 1988; 16: 485–8
   Google Scholar
• Reitamo S., Mustakallio K. K. Cyclosporin in erythrodermic psoriasis. Acta Derm Venereol 1989; Suppl 146: 140–1
   Google Scholar
• Anonymous. Management of erythrodermic psoriasis with low‐dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology 1993; 187((Suppl 1))30–7
   Google Scholar
• Meinardi M. M. H., Westerhof W., Bos J. D. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987; 116: 269–70
   PubMed Web of Science ®Google Scholar
• Matsumura N., Takematsu H., Saijo S., Hashimoto K., Togami H. Exanthematic type of pustular psoriasis consisting of two types of pustular lesion. Acta Derm Venereol 1991; 71: 442–4
   Google Scholar
• Alli N., Gungor E., Karakayali G., Lenk N., Artuz F. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol 1998; 139: 754–5
   PubMed Web of Science ®Google Scholar
• Korstanje M. J., Bessems P. J. M. J., Hulsmans R. F. H. J., van de Staak W. J. B. M. Pustular psoriasis and acrodermatitis continua (Hallopeau) need high doses of systemic cyclosporin A. Dermatologica 1989; 179: 90–4
   Google Scholar
• Fradin M. S., Ellis C. N., Voorhees J. J. Rapid response of Von Zumbusch psoriasis to cyclosporine. J Am Acad Dermatol 1990; 23: 925–6
   Google Scholar
• Coulson I. H., Evans C. D., Holden C. A. Generalised pustular psoriasis after renal transplantation – failure to suppress with cyclosporin A. Clin Exp Dermatol 1988; 13: 416–17
   Google Scholar
• Reitamo S., Puska P., Lassus A. Cyclosporin in the treatment of palmo‐plantar pustulosis. Br J Dermatol 1989; 120: 857
   PubMed Web of Science ®Google Scholar
• Meinardi M. M. H. M., de Rie M. A., Bos J. D. Oral cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris. Acta Derm Venereol 1990; 70: 77–9
   Google Scholar
• Gupta A. K., Ellis C. N., Nickoloff B. J., Goldfarb M. T., Ho V. C., Rocher L. L., et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339–50
   PubMedGoogle Scholar
• Zachariae H., Thestrup‐Pedersen K. Cyclosporin A in acrodermatitis continua. Dermatologica 1987; 175: 29–32
   Google Scholar
• Peter R. U., Ruzicka T., Donhauser G., Braun‐Falco O. Acrodermatitis continua‐type of pustular psoriasis responds to low dose cyclosporine. J Am Acad Dermatol 1990; 23: 515–16
   Google Scholar
• Arnold W. P., Gerritsen M‐JP., van de Kerkhof P. C. M. Response of nail psoriasis to cyclosporin. Br J Dermatol 1993; 129: 750–1
   Google Scholar
• Cannavo S. P., Guarneri F., Vaccaro M., Borgia F., Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo‐controlled study. Dermatology 2003; 206: 153–6
   PubMedGoogle Scholar
• Harper J. I., Zemelman V., Keat A. C. S., Staughton R. C. D. Cyclosporine for psoriasis: beneficial effect in refractory skin and joint disease. Transplant Proc 1988; 20((Suppl 4))63–7
   Google Scholar
• Steinsson K., Jonsdottir I., Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990; 49: 603–6
   PubMed Web of Science ®Google Scholar
• Gupta A. K., Matteson E. L., Ellis C. N., Ho V. C., Tellner D. C., Voorhees J. J., et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989; 125: 507–10
   PubMedGoogle Scholar
• Salvarani C., Macchioni P., Boiardi L., Rossi F., Casadei Maldini M., Mancini R., et al. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol 1992; 19: 74–9
   PubMed Web of Science ®Google Scholar
• Sarzi‐Puttini P., Cazzola M., Panni B., Turiel M., Fiorini T., Belai‐Beyene N., et al. Long‐term safety and efficacy of low‐dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002; 21: 234–8
   PubMed Web of Science ®Google Scholar
• Vaccaro M., Borgia F., Guarneri F., Blandino A., Cannavo S. P., Guarnieri B. Successful treatment of pustulotic arthro‐osteitis (Sonozaki syndrome) with systemic cyclosporin. Clin Exp Dermatol 2001; 26: 45–7
   Google Scholar
• Bougneres P. F., Carel J. C., Castano C. L., Boitard C., Gardin J. P., Landais P., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663–70
   PubMed Web of Science ®Google Scholar
• Hulton S. A., Jadresic L., Risdon R. A., Dillon M. J., Barratt T. M. Effect of cyclosporin A (CYA) on renal function in childhood nephrotic syndrome. Pediatr Nephrol 1991; 5: C25
   Google Scholar
• Collaborative study group of Sandimmun® in nephrotic syndrome. Safety and efficacy of cyclosporin A (Sandimmun®) in idiopathic nephrotic syndrome. Clin Nephrol 1991; 35: S48–S60
   Google Scholar
• Heckmatt J., Hasson N., Saunders C., Thompson N., Peters A. M., Cambridge G., et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 1063–6
   PubMed Web of Science ®Google Scholar
• Berth‐Jones J., Finlay A. Y., Zaki I., Tan B., Goodyear H., Lewis‐Jones S., et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol 1996; 34: 1016–21
   PubMed Web of Science ®Google Scholar
• Zaki I., Emerson R., Allen B. R. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996; 135((Suppl 48))21–4
   Google Scholar
• Harper J. I., Ahmed I. A., Barclay G., Lacour M., Hoeger P., Cork M. J., et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52–8
   PubMed Web of Science ®Google Scholar
• Perrett C. M., Ilchyshyn A., Berth‐Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat 2003; 14: 113–18
   PubMedGoogle Scholar
• Mahe E., Bodemer C., Pruszkowski A., Teillac‐Hamel D., de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol 2001; 137: 1532–3
   PubMedGoogle Scholar
• Cooney G. F., Habucky K., Hoppu K. Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481–95
   PubMed Web of Science ®Google Scholar
• Mason R. J., Thomson A. W., Whiting P. H., Gray E. S., Brown P. A., Catto G. R., et al. Cyclosporine induced fetotoxicity in the rat. Transplantation 1985; 39: 9–12
   PubMed Web of Science ®Google Scholar
• Gaughan W. J., Moritz M. J., Radomski J. S., Burke J. F Jr., Armenti V. T. National Transplantation Pregnancy Registry: report on outcomes in cyclosporine‐treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Am J Kidney Dis 1996; 28: 266–96
   Google Scholar
• Wright S., Glover M., Baker H. Psoriasis, cyclosporine, and pregnancy. Arch Dermatol 1991; 127: 426
   PubMedGoogle Scholar
• Raddadi A. A., Damanhoury Z. B. Cyclosporin and pregnancy. Br J Dermatol 1999; 140: 1197–8
   PubMedGoogle Scholar
• Finch T. M., Tan C. Y. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol 2000; 142: 582–4
   PubMed Web of Science ®Google Scholar
• Sowden J. M., Berth‐Jones J., Ross J. S., Motley R. J., Marks R., Finlay A. Y., et al. Double‐blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40
   PubMed Web of Science ®Google Scholar
• Young E. W., Ellis C. N., Messana S. M., Johnson K. J., Leichtman A. B., Mihatsch M. J., et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994; 46: 1216–22
   PubMed Web of Science ®Google Scholar
• Powles A. V., Hardman C. M., Porter W. M., Cook T., Hulme B., Fry L. Renal function after 10 years treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443–9
   PubMed Web of Science ®Google Scholar
• Korstanje M. J., Bilo H. J. G., Stoof T. J. Sustained renal function loss in psoriasis patients after withdrawal of low‐dose cyclosporin therapy. Br J Dermatol 1992; 127: 501–4
   PubMed Web of Science ®Google Scholar
• Zachariae H., Kragballe K., Hansen H. E., Marcussen N., Olsen S. Renal biopsy findings in long‐term cyclosporin treatment of psoriasis. Br J Dermatol 1997; 136: 531–5
   PubMed Web of Science ®Google Scholar
• Luke R. G. Mechanism of cyclosporine‐induced hypertension. Am J Hypertens 1991; 4: 468–71
   PubMed Web of Science ®Google Scholar
• Krupp P., Monka C. Side‐effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990; 122((Suppl 36))47–56
   Google Scholar
• Cainelli F., Concia E., Vento S. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis. Br J Dermatol 2000; 143: 1327–8
   Google Scholar
• Kanamori H., Fukawa H., Maruta A., Harano H., Kodama F., Matsuzaki M., et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992; 303: 109–11
   PubMed Web of Science ®Google Scholar
• Frentz G., Olsen J. H. Malignant tumours and psoriasis: a follow up study. Br J Dermatol 1999; 140: 237–42
   PubMed Web of Science ®Google Scholar
• Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B. L. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83
   PubMed Web of Science ®Google Scholar
• Paul C. F., Ho V. C., McGeown C., Christophers E., Schmidtmann B., Guillaume J. C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211–16
   PubMed Web of Science ®Google Scholar
• Olsham A. F., Mattison D. R., Zwanenburg T. S. B. Cyclosporine A: a review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutat Res 1994; 317: 163–73
   Google Scholar
• Rosenkranz H. S., Klopman G. A structural analysis of the genotoxic and carcinogenic potentials of cyclosporin A. Mutagenesis 1992; 7: 115–18
   Google Scholar
• Van den Borne B. E. E. M., Landewe R. B. M., Houkes I., Schild F., van der Heyden P. C., Hazes J. M., et al. No increased risk of malignancies and mortality in cyclosporin A‐treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930–7
   PubMed Web of Science ®Google Scholar
• Cliff S., Pettengell R., Gharge S., Marsden R. A. B‐cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis. Br J Dermatol 1999; 140: 763–5
   Google Scholar
• Koo J. Y., Kadonaga J. N., Wintroub B. V., Lozada‐Nur F. I. The development of B‐cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992; 26: 836–40
   PubMed Web of Science ®Google Scholar
• Puig L., Puig J., de Moragas J. M. Transient monoclonal gammopathy associated with cyclosporin treatment of psoriasis. Br J Dermatol 1995; 133: 149–50
   Google Scholar
• Paquet P., Pierard G. E. Breast and lung cancers in 2 cyclosporin treated psoriatic women. Dermatology 1998; 196: 450–2
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Katayama I., Nishioka K. Adenocarcinoma of the mouth in a patient with psoriasis under short term cyclosporin therapy. Dermatology 1996; 193: 72–3
   Google Scholar
• Grossman R. M., Maugee E., Dubertret L. Cervical intraepithelial neoplasia in a patient receiving long‐term cyclosporin for the treatment of severe plaque psoriasis. Br J Dermatol 1996; 135: 147–8
   Google Scholar
• Camp R. D. R. Psoriasis. Textbook of dermatology, Vol 2, R. H Champion, J. L Burton, D. A Burns, S. M Breathnach. Blackwell Scientific Publications, London 1998; 1589–650, In
   Google Scholar
• Van de Kerkhof P. C. M., De Rooij M. J. M. Multiple squamous cell carcinomas in a psoriatic patient following high‐dose photochemotherapy and cyclosporin treatment: response to long‐term acitretin maintenance. Br J Dermatol 1997; 136: 275–8
   PubMed Web of Science ®Google Scholar
• Oxholm A., Thomsen K., Menne T. Squamous cell carcinomas in relation to cyclosporin therapy of non malignant skin disorders. Acta Derm Venereol 1989; 69: 89–90
   Google Scholar
• Bos J. D., Meinardi M. M. H. M. Two distinct squamous cell carcinomas in a psoriasis patient receiving low‐dose cyclosporine maintenance treatment. J Am Acad Dermatol 1989; 21: 1305–6
   Google Scholar
• Agnew K. L., Bunker C. B. Multiple cutaneous squamous carcinoma in a psoriatic associated with cyclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol 2003; 17: 113–14
   PubMed Web of Science ®Google Scholar
• Green C., Hawk J. L. M. Cutaneous malignancy related to cyclosporin A therapy. Clin Exp Dermatol 1993; 18: 30–1
   PubMed Web of Science ®Google Scholar
• Korstanje M. J., van de Staak W. J. B. M. High cumulative dose of ultraviolet radiation is a contraindication for cyclosporin therapy. Clin Exp Dermatol 1990; 15: 76
   Google Scholar
• Marcil I., Stern R. S. Squamous‐cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet 2001; 358: 1042–5
   PubMed Web of Science ®Google Scholar
• Ross M., Goodman M. M., Barr R. J., Liao S. Y. Multiple eruptive benign keratoses associated with cyclosporine therapy for psoriasis. J Am Acad Dermatol 1992; 26: 128–9
   Google Scholar
• Yamamoto T., Watanabe K., Katayama I., Nishioka K. Multiple benign keratoses during cyclosporin therapy for psoriasis. J Dermatol 1995; 22: 298–9
   Google Scholar
• De Felipe I., Redondo P. Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis. Arch Dermatol 1998; 134: 1487–8
   PubMedGoogle Scholar
• Stiller M. J., Pak G. H., Kenny C., Jandreau L., Davis I., Wachsman S., et al. Elevation of fasting serum lipids in patients treated with low‐dose cyclosporine for severe plaque‐type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 1992; 27: 434–8
   PubMed Web of Science ®Google Scholar
• Elzinga L., Kelley V. E., Houghton D. C., Bennett W. M. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplant 1987; 43: 271–4
   PubMed Web of Science ®Google Scholar
• Stoof T. J., Korstanje M. J., Bilo H. J. G., Starink T. M., Hulsmans R. F., Donker A. J. Does fish oil protect renal function in cyclosporin‐treated psoriasis patients?. J Intern Med 1989; 226: 437–41
   Google Scholar
• Lipscombe J., Lewis G. F., Cattran D., Bargman J. M. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 39–44
   PubMed Web of Science ®Google Scholar
• Hanes D. S., Nicholson P. G., Raval D. D., Hooper F. L., Behrens M. T., Weir M. R. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant patients. Am J Ther 1997; 4: 85–91
   PubMedGoogle Scholar
• Miller D. B., Spence J. D. Clinical pharmacokinetics of fibric acid derivatives (Fibrates). Clin Pharmacokinet 1998; 34: 155–62
   PubMed Web of Science ®Google Scholar
• Bays H. E., Dujovne C. A. Drug interactions of lipid‐altering drugs. Drug Saf 1998; 19: 355–71
   PubMed Web of Science ®Google Scholar
• Christians U., Jacobsen W., Floren L. C. Metabolism and drug interactions of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol Ther 1998; 80: 1–34
   PubMed Web of Science ®Google Scholar
• Capone D., Stanziale P., Gentile A., Imperatore P., Pellegrino T., Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol 1999; 19: 411–15
   Google Scholar
• Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., et al. Accumulation of lovastatin, but not pravastatin in the blood of cyclosporine‐treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21
   PubMed Web of Science ®Google Scholar
• Rodriguez J. A., Crespo‐Leiro M. G., Paniagua M. J., Cuenca J. J., Hermida L. F., Juffe A., et al. Rhabdomyolysis in heart transplant patients on HMG‐CoA reductase inhibitors and cyclosporine. Transplant Proc 1999; 31: 2522–3
   Google Scholar
• Keogh A., Macdonald P., Kaan A., Aboyoun C., Spratt P., Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529–37
   PubMed Web of Science ®Google Scholar
• Everett D. W., Chando T. J., Didonato G. C., Singhvi S. M., Pan H. Y., Weinstein S. H. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991; 19: 740–8
   PubMed Web of Science ®Google Scholar
• Teuscher A. U., Seaquist E. R., Pittelkow M. R., Robertson R. P. Effect of long‐term cyclosporine and long‐term prednisone therapy on insulin secretory reserve. Schweiz Med Wochenschr 1994; 124: 2036–8
   Google Scholar
• Krentz A. J., Dousset B., Mayer D., McMaster P., Buckels J., Cramb R., et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993; 42: 1753–9
   Google Scholar
• Neto A. B., Haapalainen E., Ferreira R., Feo C. F., Misiako E. P., Vennarecci G., et al. Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets. Transplant Int 1999; 12: 208–12
   Google Scholar
• Goldman M. Uric acid in the etiology of psoriasis. Am J Dermatopathol 1981; 3: 397–404
   PubMed Web of Science ®Google Scholar
• Zurcher R. M., Bock H. A., Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin‐A‐treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9: 548–51
   PubMedGoogle Scholar
• Thiel G., Bock A., Spondlin M., Brunner E. P., Mihatsch M., Rufli T., et al. Long‐term benefits and risks of cyclosporin A (sandimmun) – an analysis at 10 years. Transplant Proc 1994; 26: 2493–8
   PubMed Web of Science ®Google Scholar
• De Rie., Meinardi M. M. H. M., Bos J. D. Analysis of side effects of medium‐ and low‐dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol 1990; 123: 347–53
   Google Scholar
• Balletta M., Libetta C., Fuiano G., Delfino M., Brunetti B., Ungaro B., et al. Effects of a two‐month treatment with low oral doses of cyclosporin on renal function. Nephrol Dial Transplant 1991; 6: 324–9
   Google Scholar
• Kirby B., Rogers S. Gingival hyperplasia in psoriasis patients treated with cyclosporin. Br J Dermatol 2000; 25: 96–9
   Google Scholar
• Thami G. P., Bhalla M. Erythromelalgia induced by possible calcium channel blockade by cyclosporin. BMJ 2003; 326: 910
   Google Scholar
• Cacoub P., Artru L., Canesi M., Koeger A. C., Camus J. P. Life‐threatening psoriasis relapse on withdrawal of cyclosporin. Lancet 1988; II: 219–20
   Google Scholar
• Heidenheim M., Oxholm A., Da Cunha Bang F. Generalised pustular psoriasis in relation to withdrawal of cyclosporin A. Br J Dermatol 1990; 122: 719
   Google Scholar
• Mahendran R., Grech C. Generalised pustular psoriasis following a short course of cyclosporin (Neoral). Br J Dermatol 1998; 139: 934
   Google Scholar
• Georgala S., Koumantaki E., Rallis E., Papadavid E. Generalized pustular psoriasis developing during withdrawal of short‐term cyclosporin therapy. Br J Dermatol 2000; 142: 1047–70
   Google Scholar
• Kamarashev J., Lor P., Forster A., Heinzerling L., Burg G., Nestle F. O. Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002; 205: 213–16
   PubMed Web of Science ®Google Scholar
• De Silva B. D., Benton E. C., Tidman M. J. Generalised pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo‐plantar pustulosis. Clin Exp Dermatol 1999; 24: 10–13
   Google Scholar
• Ho V. C., Griffiths C. E. M., Albrecht G., Vanaclocha F., Leon‐Dorantes G., Atakan N., et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy. Br J Dermatol 1999; 141: 283–91
   PubMed Web of Science ®Google Scholar
• Berth‐Jones J., Voorhees J. J. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 1996; 135: 775–7
   PubMedGoogle Scholar
• Oztas P., Gurer M. A. The evaluation of the effectiveness and side‐effects of a 200‐mg/day constant dose of cyclosporin in chronic plaque‐type psoriasis: can a constant dose be an alternative?. J Eur Acad Dermatol Venereol 2004; 18: 103–4
   Google Scholar
• Thaçi D., Bräutigam M., Kaufmann R., Weidinger G., Paul C., Christophers E. Body‐weight‐independent dosing of cyclosporine micro‐emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002; 205: 383–8
   PubMed Web of Science ®Google Scholar
• Ho V. C. Y., Griffiths C. E. M., Berth‐Jones J., Papp K. A., Vanaclocha F., Dauden E., et al. Intermittent short courses of cyclosporine microemulsion for the long‐term management of psoriasis: a 2‐year cohort study. J Am Acad Dermatol 2001; 44: 643–51
   PubMed Web of Science ®Google Scholar
• Ohtsuki M., Nakagawa H., Sugai J., Ozawa A., Ohkido M., Nakayama J., et al. Long‐term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol 2003; 30: 290–8
   PubMed Web of Science ®Google Scholar
• Korstanje M. J. Cyclosporin A administration in dermatology: once a day or in fractional doses?. Arch Derm Res 1990; 281: 536–7
   Google Scholar
• Meinardi M. M., Bos J. D. Cyclosporine maintenance therapy in psoriasis. Transplant Proc 1988; 20((Suppl 4))42–9
   Google Scholar
• Munro C. S., Levell N. J., Shuster S., Friedmann P. S. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994; 130: 376–80
   PubMed Web of Science ®Google Scholar
• Harper S. J., Moorhouse J., Abrams K., Jurewicz A., Nicholson M., Horsburgh T., et al. The beneficial effects of oral nifedipine on cyclosporin‐treated renal transplant recipients – a randomised population study. Transplant Int 1996; 9: 115–25
   Google Scholar
• McNally P. G., Walls J., Feehally J. The effect on renal function in normotensive cyclosporin‐A‐treated renal allograft recipients. Nephrol Dial Transplant 1990; 5: 962–8
   PubMedGoogle Scholar
• Edwards B. D., Chalmers R. J. G., O'Driscoll J., Lawson R. S., Testa H. J., Ballardie F. W. Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low‐dose cyclosporin. Nephrol Dial Transplant 1993; 8: 1071–8
   Google Scholar
• McCulloch T. A., Harper S. J., Donnelly P. K., Moorhouse J., Bell P. R., Walls J., et al. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 1994; 47: 839–42
   PubMedGoogle Scholar
• Raman G. V., Campbell S. K., Farrer A., Albano J. D., Cook J. Modifying effects of amlodipine on cyclosporin A‐induced changes in renal function in patients with psoriasis. J Hypertens Suppl 1998; 16: S39–S41
   Google Scholar
• Neumayer H. H., Kunzendorf U., Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992; 36(Suppl): S87–S93
   Google Scholar
• Chan C., Maurer J., Cardella C., Cattran D., Pei Y. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63: 1435–40
   Google Scholar
• Deray G., Baumelou B., Le Hoang P., Aupetit B., Girard B., Baumelau A., et al. Enhancement of cyclosporin nephrotoxicity by diuretic therapy. Clin Nephrol 1989; 32: 47
   Google Scholar
• Feutren G., Miller C. Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome. Transplant Proc 1990; 22: 1299–302
   PubMed Web of Science ®Google Scholar
• Young E. W., Ellis C. N., Messana J. M., Johnson K. J., Leichtman A. B., Mihatsch M. J., et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994; 46: 1216–22
   PubMed Web of Science ®Google Scholar
• Pei Y., Scholey J. W., Katz A., Schachter R., Murphy G. F., Cattran D. Chronic nephrotoxicity in psoriatic patients treated with cyclosporine. Am J Kidney Dis 1994; 23: 528–36
   PubMed Web of Science ®Google Scholar
• Heydendael V. M., Spuls P. I., Ten Berge I. J., Opmeer B. C., Bos J. D., de Rie M. A. Cyclosporin trough levels: is monitoring necessary during short‐term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol 2002; 147: 122–9
   PubMed Web of Science ®Google Scholar
• Lindholm A., Zachariae H., Reitamo S., Ibsen H. H., Oxholm A., Reunala T., et al. Is cyclosporine blood concentration monitoring necessary in patients treated for severe chronic plaque form psoriasis?. Transplant Proc 1990; 22: 1293–5
   PubMed Web of Science ®Google Scholar
• Korstanje M. J., Bilo H. J. G., Stoof T. J. Sustained renal function loss in psoriasis patients after withdrawal of low‐dose cyclosporin therapy. Br J Dermatol 1992; 127: 501–4
   PubMed Web of Science ®Google Scholar
• Powles A. V., Cook T., Hulme B., Baker B. S., Lewis H. M., Thomas E., et al. Renal function and biopsy findings after 5 years' treatment with low‐dose cyclosporin for psoriasis. Br J Dermatol 1993; 128: 159–65
   PubMed Web of Science ®Google Scholar
• García‐Bustínduy M., Escoda M., Guimerá F. J., Saez M., Dorta S., Fagundo E., et al. Safety of long‐term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol 2004; 18: 169–72
   PubMed Web of Science ®Google Scholar
• Markham T., Watson A., Rogers S. Adverse effects with long‐term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002; 27: 111–14
   PubMed Web of Science ®Google Scholar
• Kelly P. A., Wang H., Napoli K. L., Kahan B. D., Strobel H. W. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 1999; 24: 321–8
   PubMed Web of Science ®Google Scholar
• Durr D., Steiger B., Kullak‐Ublick G. A., Rensch K. M., Steinert H. C., Meier P. J., et al. St John's wort induces intestinal P‐glycoprotein/MDR1 and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598–60
   PubMed Web of Science ®Google Scholar
• Moore L. B., Goodwin B., Jones S. A., Wisely G. B., Serabjit‐Singh C. J., Willson T. M., et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500–2
   PubMed Web of Science ®Google Scholar
• Karliova M., Treichel U., Malago M., Frilling A., Gerken G., Broelsch C. E. Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853–5
   PubMed Web of Science ®Google Scholar
• Ducharme M. P., Provenzano R., Dehoorne‐Smith M., Edwards D. J. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457–9
   PubMed Web of Science ®Google Scholar
• Herlitz H., Edgar B., Hedner T., Lidman K., Karlberg I. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant 1993; 8: 375
   Google Scholar
• Yee G. C., Stanley D. L., Pessa L. J., Dalla Costa T., Beltz S. E., Ruiz J., et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955–6
   PubMed Web of Science ®Google Scholar
• Bistrup C., Nielsen F. T., Jeppesen U. E., Dieperink H. Effect of grapefruit juice on Sandimmun NeoralTM absorption among stable renal allograft recipients. Nephrol Dialysis Transpl 2001; 16: 373–7
   PubMed Web of Science ®Google Scholar
• Bailey D. G., Arnold J. M. O., Spence J. D. Grapefruit juice and drugs: how significant is the interaction?. Clin Pharmacokinet 1994; 26: 91–8
   PubMedGoogle Scholar
• Gueco I. P., Tan‐Torres T., Baniga U., Alano F. Ketoconazole in posttransplant triple therapy: comparison of costs and outcomes. Transplant Proc 1992; 24: 1709–14
   Google Scholar
• First M. R., Schroeder T. J., Michael A., Hariharan S., Weiskittel P., Alexander J. W. Safety and efficacy of long‐term cyclosporine‐ketoconazole administration and preliminary results of a randomized trial. Transplant Proc 1993; 25: 591–4
   Google Scholar
• Moody H. R., Bickell‐Feist L., Friesen I., Huizinga R., Halloran PF., et al. Benefits of cyclosporine dose reduction using diltiazem. Clin Invest Med 1991; 14(Suppl): A142
   Google Scholar
• Patton P. R., Brunson M. E., Pfaff W. W., Howard R. J., Peterson J. C., Ramos E. L., et al. A preliminary report of diltiazem and ketoconazole: their cyclosporine‐sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889–92
   Google Scholar
• Anonymous. Cyclosporin‐sparing agents provide potential economic benefit. Drugs & Therapy Perspectives 2001; 17: 12–15
   Google Scholar
• Martell R., Heinrichs D., Stiller C. R., Jenner M., Keown P. A., Dupre J. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 1986; 104: 660–1
   PubMed Web of Science ®Google Scholar
• Freeman D. J., Martell R., Carruthers S. G., Keown P. A. The effect of erythromycin on the pharmacokinetics of cyclosporine. Clin Pharmacol Ther 1986; 39: 193
   Google Scholar
• Branthwaite J. P., Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis. Lancet 1991; 337: 252
   Google Scholar
• Harris K. P., Jenkins D., Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. A potentially serious adverse interaction. Transplantation 1988; 46: 598–9
   Google Scholar
• Grossman R. M., Thivolet J., Claudy A., Souteyrand P., Guilhou J. J., Thomas P., et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low dose cyclosporine: results of a multicenter placebo‐controlled study. J Am Acad Dermatol 1994; 31: 68–74
   PubMed Web of Science ®Google Scholar
• Kokelj F., Torsello P., Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Derm Venereol 1998; 10: 143–6
   PubMed Web of Science ®Google Scholar
• Gottlieb S. L., Heftler N. S., Gilleaudeau P., Johnson R., Vallat P., Wolfe J., et al. Short‐contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol 1995; 33: 637–45
   Google Scholar
• Griffiths C. E. M., Powles A. V., Baker B. S., Fry L., Valdimarsson H. Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis. Transplant Proc 1988; 20((Suppl 4))50–2
   Google Scholar
• Clark C. M., Kirby B., Morris A. D., Davison S., Zaki I., Emerson R., et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279–82
   PubMed Web of Science ®Google Scholar
• Brechtel B., Wellenreuther U., Toppe E., Czarnetzki B. M. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol 1994; 30: 1023–4
   Google Scholar
• Heule F., Bousema T., Laeijendecker R., vna Joost T. Three long‐term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol (Suppl) 1989; 146: 171–5
   Google Scholar
• Korstanje M. J., Bessems P. J. M. J., van de Staak W. J. B. M. Combination therapy cyclosporin‐etretinate effective in erythrodermic psoriasis. Dermatologica 1989; 179: 94
   Google Scholar
• Korstanje M. J., Van de Staak W. J. B. M. Combination therapy cyclosporin A etretinate for psoriasis. Clin Exp Dermatol 1990; 15: 172–3
   Google Scholar
• Shah I. A., Whiting P. H., Omar G., Ormerod A. D., Burke M. D. The effects of retinoids and terbinafine on human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 1993; 129: 395–8
   Google Scholar
• Kirby B., Harrison P. V. Combination low dose CyA (Neoral) and hydroxyurea for severe recalcitrant psoriasis. Br J Dermatol 1999; 140: 186–7
   Google Scholar
• Balasubramaniam P., Stevenson O., Berth‐Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150: 741–6
   PubMed Web of Science ®Google Scholar
• Ameen M., Smith H. R., Barker J. N. W. N. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001; 26: 480–3
   PubMed Web of Science ®Google Scholar
• Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., Griffiths C. E., et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438–45
   PubMed Web of Science ®Google Scholar
• Petzelbauer P., Honigsmann H., Langer K., Strohal R., Tanew A., Wolff K., et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 1990; 123: 641–7
   Google Scholar
• Bell H. K., Parslew R. A. Use of basiliximab as a cyclosporin‐sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. Br J Dermatol 2002; 147: 606–7
   PubMed Web of Science ®Google Scholar
• Mahe E., Descamps V., Grossin M., Fraitag S., Crickx B. CD30+ T‐cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149: 170–3
   PubMedGoogle Scholar
• Weinstein G. D., White G. M. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454–9
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new treatment paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: S25–S28
   PubMed Web of Science ®Google Scholar